417717-21-6

Desamino Hydroxy Lenvatinib serves as a reagent for the synthesis of urea derivatives containing nitrogenous aromatic ring compounds that functions as angiogenesis inhibitors for treatment of diseases. It is also a derivative compound of Lenvatinib (L329400) that serves as orally active inhibitor of multiple receptor tyrosine kinases including VEGF, FGF and SCF receptors.